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ABSTRACT 
MicroRNAs (miRs) play a vital role in governing cell function, with their levels 
tightly controlled at transcriptional and post-transcriptional levels. Different sets of 
RNA-binding proteins (RNA-BPs) interact with primary (pri-) miRs and precursor 
(pre-) miR transcripts, controlling their biogenesis post-transcriptionally. The Hu 
antigen R (HuR)-mediated binding of Musashi homolog2 (MSI2) to the Conserved 
Terminal Loop (CTL) of pri-miR-7 regulates the levels of brain-enriched miR-7 
formation in a tissue specific manner. Here we show that Oleic Acid (OA) inhibits 
binding of proteins containing RNA recognition motifs (RRM) to the CTL of pri-
miR-7. Using EMSA assays in HeLa cell extracts we show that OA treatment disrupts 
pre-miR/protein complexes. Furthermore, Oleic Acid rescues in vitro processing of 
pri-miR-7, which is otherwise blocked by HuR and MSI2 proteins. On the contrary, 
pri-miR-16 shows reduced processing in the presence of OA. This indicates that OA 
may inhibit binding of other RRM-containing protein/s necessary for miR-16 
processing. Finally, we demonstrate that OA induces mature miR-7 production in 
HeLa cells. Together our results demonstrate that OA can regulate the processing of 
pri-miRs by remodelling their protein complexes. This provides a new tool to study 
RNA processing as well as a potential lead for small molecules that target the miR-7 
biogenesis pathway. 
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INTRODUCTION 
Small non-coding RNAs called microRNAs (miRs) constitute a large family of short 
(21-23 nucleotide) RNAs which guide gene regulation in diverse and complex 
patterns [1]. In most metazoan tissues, microRNAs constitute the dominating class of 
small RNA regulators [2, 3]. These RNAs regulate the expression of their target 
mRNAs in complex with ribonucleoproteins also known as miRNPs. [4]. microRNA 
mediated downregulation of gene expression can occur either by decreased mRNA 
stability or translational inhibition [5]. Thus, the levels of these small regulators are 
tightly adjusted to control the final protein levels in the cell. Production of 
microRNAs can be controlled either at the transcriptional level by RNA pol II 
associated transcription factors or at the post-transcriptional levels to modulate the 
processing steps of microRNA biogenesis [2, 6, 7]. Post-transcriptional regulation of 
microRNA biogenesis is predominantly achieved by binding of different classes of 
RNA-binding proteins (RNA-BPs) to their precursors or primary transcripts, as well 
as by regulating their stability and subcellular localization [8]. Binding of these RNA-
BPs, particularly to the terminal loop of pri- and pre-miRs, can act either as a 
repressor or activator signal for microRNA biogenesis [9-13].  
 
Deregulation of microRNA levels is often linked with various pathological conditions 
including cancer and neurodegenerative disorders [14-17]. MiR-7, which was 
originally characterized as a potential tumour suppressor, has been extensively studied 
in various human cancers and has been shown to regulate diverse biological processes 
in cancer cells [18, 19]. The biogenesis of miR-7 is regulated at both transcriptional 
and post-transcriptional levels involving various transcription factors [20-22] and 
RNA-BPs [10, 23, 24]. MiR-7 directly binds to the 3`-UTR of the epidermal growth 
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factor receptor (EGFR) mRNA which leads to subsequent inhibition of its expression 
[25]. Notably, inefficient processing of miR-7 has been shown to be the cause of its 
reduced levels in glioblastoma multiforme (GBM) cells as compared to the 
surrounding brain tissue [25]. The RNA-BP HuR/ELAV1 has been implicated in 
regulating microRNA biogenesis as knockdown of HuR triggers the upregulation of 
miR-7 [23]. Recently, we have shown that HuR-mediated recruitment of another 
RNA-BP - MSI2 to the Conserved Terminal Loop (CTL) of miR-7 plays an important 
role in the tissue-specific control of miR-7 biogenesis [10]. Thus, the miR-7-MSI2-
HuR ternary complex represents a potential therapeutic target for GBM. HuR has also 
been implicated in regulating biogenesis of other microRNAs, such as miR-133 [26] 
and miR-199 [27]. 
 
Oleic Acid (OA), the monounsaturated fatty acid, has recently been shown to inhibit 
the RNA binding activity of the MSI1 and MSI2 proteins [28]. It does so by binding 
to the N-terminal RNA recognition motif (RRM) and inducing an allosteric change to 
the protein conformation, thereby preventing RNA binding [28]. Thus, in theory the 
inhibitory action of oleic acid against the MSI2 protein could be utilized to disrupt 
miR-7-MSI2-HuR ternary complex formation and rescue the biogenesis of miR-7. On 
the other hand, Elaidic Acid (EA), which is a trans-isoform of OA and has the same 
molecular weight, similar refractive index and molar aqueous solubility as OA, does 
not bind to MSI1. Fatty acids such as oleic acid and elaidic acid occur naturally in 
various organisms. They are components of membranes, provide energy and serve as 
biologically active molecules. Physiologically normal serum contains high M to low 
mM concentration of oleic acid [29]. However, during various pathophysiological 
conditions the levels of OA are known to rise drastically sometimes up to high mM 
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concentrations [30-32]. Oleic acid makes the highest content of the fatty acids in 
adipose tissue [33], even though elaidic acid is the most abundant trans fatty acid 
present in the diet [34]. OA is also present in intracellular lipid droplets [35]. 
 
Here, using EMSA analysis we show that both OA and EA both can inhibit the 
binding of RNA-BPs to pre-miR-7. Moreover, in vitro processing of pri-miR-7 in 
HeLa cell extracts demonstrates that the presence of OA rescues miR-7 maturation. 
We show that treatment of HeLa cells with OA but not EA induces the production of 
miR-7. Finally, we show that OA does not affect the levels of several control 
microRNAs. These results suggest that OA can be important and specific regulator of 
RNA processing events. 
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RESULTS AND DISCUSSION 
 
Oleic Acid (18:1 ω-9) monounsaturated fatty acid potently inhibits the binding of 
RNA-BPs to pre-miR-7-1  
Oleic Acid is the most abundant and widely distributed fatty acid in nature. It is an 
eighteen-carbon monounsaturated fatty acid with one double bond present at the 9th 
carbon atom from the aliphatic omega end of the molecule (18:1, ω-9) (Fig. 1a). It has 
been shown to inhibit the binding of MSI1 and MSI2 proteins to their mRNA target in 
a very strong and specific manner [28]. On the other hand, Elaidic Acid, which is a ω-
9 trans isomer of OA, demonstrated no inhibition at all. Our previous results showed 
that pri-miR-7-1 and miR-7-1 CTL bind HuR and MSI2 proteins (Fig. 1b) [10]. To 
test if fatty acids interfere with pri-miR-7/protein complex we performed EMSA 
experiments to monitor the binding of cognate proteins to the pre-miR-7. Incubation 
of pre-miR-7 with HeLa cell extract shifted the free RNA, indicating binding of 
specific proteins to the RNA structure (Fig. 1c). Treatment with OA showed a 
decrease in the intensity of the shifted band in a concentration dependent manner (Fig. 
1d), suggesting inhibition of complex formation between proteins and precursor miR-
7. This observation supports the earlier findings by Clingman et al. where they 
showed that OA binds to MSI2 and induces an allosteric conformational change to 
inhibit RNA binding. However, in contrast to the earlier report Elaidic Acid treatment 
also inhibited binding of cognate proteins in a concentration dependent manner (Fig. 
1c). Densitometry analysis showed that the effect of the EA treatment is relatively 
smaller compared to OA at the same concentrations (Fig. 1d).  
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Next to validate that the aggregates seen in EMSA are RNA-binding proteins 
interacting with pre-miR-7 we used a modified EMSA with pre-miR-7, which was 
transferred to nitrocellulose and blotted against HuR and DHX9 (Fig. 2). This 
approach, called western blot-combined EMSA (WEMSA), positively identified HuR 
(Fig. 2a) and DHX9 (Fig. 2b) as components of the pre-miR-7/protein complex in 
HeLa cell extracts. Furthermore, it also revealed that OA treatment inhibited HuR 
binding to pre-miRs to much greater extent than EA. Notably, control EMSA with 
pre-let-7a-1 and pre-miR-16 showed that both OA and EA treatments did not 
significantly affect the RNA-protein complexes formed by pre-let-7a-1 (Fig. 3) and 
affected pre-miR-16 complex only at the 1 mM concentration (Fig. 4). These results 
indicate that there is some level of selectivity of OA and EA towards pre-miR-7 in 
vitro. 
 
The fact that both OA and EA are disrupting pre-miR-7/protein complex disagrees 
with the earlier observation by Clingman and colleagues [28], where they observed no 
inhibition of RNA-protein interaction upon EA treatment, could arise from 
experimental factors. One explanation for the observed differences in EA action could 
be the fact that they worked with purified MSI2 protein whereas we monitored the 
binding of protein factors extracted from HeLa cells. Thus, the difference in the 
inhibitory potency of the two fatty acids could possibly stem from their differential 
binding strength to endogenous proteins as compared to recombinant proteins. 
Moreover, we used much higher concentrations of OA and EA to observe the effects. 
In the present study, the solubility of these fatty acids was not measured but earlier 
report suggests that OA and EA both have similar molar aqueous solubility (~10 mM 
at pH 8.0) [28]. Thus, our working concentration of OA and EA was well below the 
Kumar S et al. 8 
maximum aqueous solubility of these acids, which dismisses the possibility of 
insoluble aggregate formation.  
 
Oleic acid disrupts the binding of RRM containing proteins to the CTL of pri-
miR-7-1 
Next, to investigate the effects of OA/EA on pre-miR-7-protein complex we 
performed RNA pull-down assay in HeLa cell extracts using the miR-7 CTL 
conjugated to agarose beads. This assay allows for efficient and specific capture of 
the proteins bound to the candidate RNA molecule. Western blot analysis was 
performed for selected RRM containing RNA-BPs (MSI2, HuR and hnRNP A1) and 
a dsRNA-specific binding protein DHX9, which is a DEAH box containing RNA 
helicase. These proteins were chosen based on an earlier report where they were 
shown to interact specifically with the miR-7 CTL [10]. Another reason for choosing 
these proteins is that OA is known to inhibit the binding of MSI1 and MSI2 by 
binding to their RRMs thereby inducing a conformational change to prevent RNA 
binding [28]. HuR, MSI2 and hnRNP A1 proteins showed no significant effect in 
their RNA pull-down assay at lower concentrations of OA and EA treatment (Fig. 5). 
However, with 500 μM of OA the binding of HuR, MSI2 and hnRNP A1 proteins was 
completely abolished (Fig. 5). EA treatment at 500 μM also resulted in complete 
abolishment of HuR and hnRNP A1 binding to the miR-7 CTL, while MSI2 binding 
was reduced. Additionally, the binding of DHX9 was monitored to examine if OA 
and EA treatment inhibit the binding of other types of RNA-BPs or only the RRM 
containing proteins. Western blot analysis of DHX9 showed no effect of OA and EA 
treatment on DHX9 binding to the CTL of miR-7 (Fig. 5). This suggests that 
differential binding of OA and EA to RRM containing proteins leads to inhibition of 
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RNA-protein complex formation; however, dsRNA-BP remains unaffected. This also 
explains the disparity in the concentrations of the fatty acids needed to achieve 
complete dissociation of all proteins in EMSA assays. In the EMSA experiment there 
was a gradual reduction in the total amount of proteins bound to the RNA structure 
even at 1 mM of acid treatment suggesting that the fatty acid treatment does not 
inhibit binding of all the RNA-BPs. 
 
The biogenesis of miRs in HeLa cell extract is influenced by OA and EA 
treatment 
As evident from earlier studies the biogenesis of miR-7 is altered in HeLa cells owing 
to the presence of MSI2 and HuR bound to the CTL of the pri-miR-7 [10]. Binding of 
these trans-acting proteins inhibits the microprocessor-mediated processing. Thus, 
OA and EA could be used to restore miR-7 biogenesis. To verify this, we performed 
in vitro processing of pri-miR-7-1 in HeLa cell extracts in the presence of increasing 
concentrations of OA and EA. We showed that treatment with both OA and EA could 
rescue miR-7 processing (Fig. 6a, b). The effect was only seen at 1 mM fatty acid 
concentration most likely arising from reduced sensitivity of in vitro processing 
assays. Binding of trans-acting proteins to the terminal loop of pri-miR-7-1 was 
inhibited by OA and EA, thus leading to a noticeable increase in microprocessor 
activity generating pre-miR-7. Importantly, these results demonstrate that the 
presence of OA and EA does not inhibit Drosha. We speculate that OA (and likely 
EA also) binds to RRM containing RNA-BPs only and does not affect binding of 
other RNA-BPs which are necessary for the microprocessor activity [36].  
 
The biogenesis of miR-16 is inhibited by OA and EA treatment 
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To obtain more mechanistic insights into OA and EA binding we chose to analyse the 
processing of miR-16. The levels of miR-16 remained unaffected upon MSI2 or HuR 
downregulation [10]. Moreover, miR-16 has been used in many studies as an internal 
control, as it is ubiquitously expressed and its level remains relatively stable during 
the cell lifecycle [37, 38]. Interestingly, when we performed in vitro processing of pri-
miR-16 in the presence of OA and EA we observed concentration-dependent 
inhibition of pri-miR-16 processing (Fig. 6c, d). This result implies that RRM 
containing protein factor/s could regulate the biogenesis of miR-16. However, further 
experiments, which are needed to test this hypothesis are beyond the scope of this 
paper. Nonetheless, these results clearly demonstrate that different sets of trans-acting 
proteins are required to regulate levels of various microRNAs.  
   
OA treatment rescues mature miR-7 production in cells 
The effect of OA and EA treatment was assessed in HeLa cells by monitoring the 
levels of mature miR-7 using qRT-PCR. Previously it was shown that downregulation 
of MSI2 or HuR individually or in combination resulted in rescue of pri-miR-7 
processing leading to a two-fold increase in the levels of mature miR-7 [10]. We 
subsequently treated HeLa cells with various concentrations of OA and EA for 24 h 
and monitored the levels of mature miR-7 by qRT-PCR. At concentrations, higher 
than 100 μM the cells were not viable, thus in standard cell culture conditions we had 
to use suboptimal concentrations of OA and EA. Additionally, we chose to normalise 
the miR-7 levels to total RNA to avoid the possibility of bias resulting from OA-
mediated regulation of other endogenous RNAs. Importantly, these results showed a 
concentration dependent increase in the levels of miR-7 at lower concentrations of 
OA, up to 50 μM (Fig. 7a). However, 100 μM OA treatment exhibited a smaller 
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increase in miR-7 levels, suggesting additional, toxic effects of OA at this 
concentration (Fig. 7a). Interestingly, EA did not trigger an increase in the miR-7 
levels in the concentrations up to 100 μM (Fig. 7b). Notably, standard cell culture 
medium already contains high levels of fatty acids [29]. For this reason, we modified 
our analysis in HeLa cells and cultured them in Opti-MEM without serum. This 
allowed us to use similar OA concentrations to those from the in vitro experiments, 
without compromising cellular fitness.  This resulted in a smaller but still statistically 
significant increase of mature miR-7 upon OA treatment (Fig. 7c). In these conditions 
miR-16 levels did not change and thus we have used it as a normalization control 
towards let-7a-1 and miR-423, which also remained constant (Fig. 7c). Together, 
these results clearly demonstrate that OA treatment increases the levels of mature 
miR-7 in HeLa cells. Moreover, this also indicates that the presence of OA does not 
alter the global activity of the microprocessor. This is important as microprocessor 
has been shown to be involved other cellular processes such as splicing [39] or gene 
expression [40].  
 
The levels of polyunsaturated fatty acids, for which oleic acid is a precursor, are more 
tightly controlled than saturated fatty acids owing to their diverse roles in the 
mammalian physiology. Oleic acid treatment on the glial cells suppresses lipogenesis 
and cholesterologensis [41]. In colorectal cancer patients the levels of oleic acid are 
significantly higher than the levels of most saturated fatty acids [42]. On the contrary 
oleic acid levels are significantly reduced in Alzheimer’s disease patients [43]. Thus, 
it is possible that fluctuation of the oleic acid levels can change cellular metabolism, 
which could lead to pathophysiological conditions. Studying the effects of fatty acids, 
such as oleic acid, on the microRNA biogenesis and RNA processing in general could 
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uncover novel regulatory pathways involved in cellular homeostasis. These studies 
could also provide an entry point towards designing potential drug molecules that 
target microRNA biogenesis pathway. In the case of glioblastoma multiforme the 
levels of miR-7 are post-transcriptionally downregulated [25]. Therefore, drugs based 
on natural compounds, such as oleic acid, could bypass delivery issues surrounding 
microRNA replacement strategies in the brain. This would be feasible as fatty acids 
are known the cross the blood brain barrier [44]. In summary, our results suggest that 
mono unsaturated fatty acids can regulate the binding of RRM-containing RNA-BPs 
to their target RNAs and any change in the cellular concentration of fatty acids might 
lead to complex rewiring of the cellular processes. Further work needs to be done to 
understand the specific roles of fatty acids in regulating RNA processing. 
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In this study, we have explored the inhibitory action of OA against the RNA-binding 
proteins involved in the inhibition of miR-7 biogenesis. We demonstrated that OA not 
only inhibits the binding of MSI2 protein but also interferes with other RRM-
containing RNA-BPs known to bind to the miR-7 CTL. More interestingly OA 
treatment showed opposite effects on the in vitro processing of the pri-miR-7 and pri-
miR-16. This indicates various requirements for the trans-acting protein factors that 
play positive and negative roles in the control of their processing. Further studies need 
to be performed to unravel the specific proteins necessary for the regulation of miR-
16 biogenesis. Earlier [28] EA had been shown to have no effect on the MSI2 RNA-
binding activity. However, we found that EA also inhibits the binding of RRM-
containing RNA-BPs, although in higher concentrations and to a lower extent. We 
propose that OA can be used as a molecular tool to study the regulation of RNA 
processing as well as providing an entry point into designing therapies targeted at 
miR-7 biogenesis pathways. 
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MATERIALS AND METHODS 
Primers and RNA sequences 
The CTL sequence of miR-7-1 (5´-UGU UGU UUU UAG AUA ACU AAA UCG 
ACA ACA AA- 3´) was purchased from Sigma Aldrich and dissolved in water to 
make a 1 nmol/μL stock. The pri-miR-7-1, pre-miR-7-1, pre-miR-16 and pre-let-7a-1 
sequences were amplified from the pCG-T7 mammalian expression vectors 
containing corresponding sequences and prepared as described previously [10].  
 
RNA pull-down assay and western blot analysis 
RNA pull-down assays were based on a method described previously [45]. HeLa cell 
extracts were prepared by collecting ~3 × 106 cells in 1 mL of buffer D (20 mM Tris-
HCl at pH 7.9, 20% p/v glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol, 
0.2 mM PMSF) and sonicating 10 × 30s on/off using a temperature controlled water 
bath sonicator. Immobilization of RNA to agarose beads and affinity purification of 
proteins was performed using a previously published protocol [46]. Oleic acid [≥99% 
(GC)] and Elaidic acid [≥99% (GC)] were purchased from Sigma-Aldrich. Following 
pull-down experiment the proteins were separated using a 4-12 % gradient Bis-tris gel 
(NuPAGE Novex, Invitrogen) and transferred on to a nitrocellulose membrane 
(Whatman) in 25 mM Tris-base, 40 mM glycine and 10 % (v/v) methanol using a 
Genie blotter unit (Idea scientific company) at 12 V for 1 h. After transfer, the 
membrane was blocked with western blocking solution (Roche) diluted in 1:10 using 
TBS-T (20 mM Tris at pH 7.5, 137 mM NaCl, 0.1 % v/v Tween 20). Specific proteins 
were detected using the primary antibodies in western blocking solution, (diluted 1:20 
in TBS-T) and incubated for 1 h at room temperature. The following dilutions of the 
primary antibodies were used; rabbit polyclonal anti-MSI2 (1:1000; clone EP1305Y, 
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Millipore), rabbit polyclonal anti-HuR (1:1000; Millipore), rabbit polyclonal anti-
DNX9 (1:1000; Proteintech) and mouse monoclonal anti-hnRNP A1 (clone 4B10; 
1:1000; Santa Cruz Biotechnology). After incubation in primary antibodies the blot 
was washed with TBS-T for 3 × 5 min and incubated with the appropriate secondary 
antibody conjugated with horseradish peroxidase (HRP). These bound secondary 
antibodies were then visualized using SuperSignal west Pico detection reagent 
(Thermo Scientific) and film. The membrane was reblotted after stripping with 
ReBlot Plus Strong antibody-stripping solution (Chemicon) diluted 1:10, in water and 
blocking the membrane using western blocking solution in TBS-T. 
 
Electrophoretic mobility shift assay (EMSA) and western blot-combined EMSA 
(WEMSA) 
Pre-miRs were synthesized by in vitro transcription and 32P α-UTP was used for body 
labelling of the RNA. Radiolabelled pre-miRs were purified by running 10 % 
denaturing PAGE in 1 × TBE (89 mM Tris; pH 7.5, 89 mM Boric acid, 2 mM 
EDTA). Radiolabelled pre-miRs were incubated with HeLa cell extract in the absence 
and presence of different concentrations of the OA and EA on ice for 1 h before 
loading on to the gel. Free and protein bound RNA was separated on 6 % non-
denaturing PAGE by running in 0.5 × TBE at 8 Watts. The gel exposed phosphor 
screen was scanned using a Fujifilm FLA 5000 scanner. Image analysis and 
quantitation was performed using Aida Image analyser V.4.27 software. For WEMSA 
after PAGE the proteins were transferred on to a nitrocellulose membrane. 
Subsequent protein detection was carried out as in western blot analysis.  
 
In vitro processing assay 
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Pri-miR-7-1 and pri-miR-16 were synthesized by in vitro transcription using plasmids 
containing respective sequences as templates in the presence of 32P α-UTP [10]. 
Radiolabeled pri-miRs (~30,000 c.p.m.) were incubated with 50 % HeLa cell extract 
either in the presence or absence of OA and EA and processing was performed at 37 
°C for 30 min with 0.5 mM ATP, 20 mM creatine phosphate, 3.2 mM MgCl2. Next, 
phenol chloroform extraction was performed followed by precipitation and separation 
on 8 % denaturing PAGE in 1 × TBE. 
 
Real time qRT-PCR 
HeLa cells were seeded in a 6 well plate and treated with different concentrations of 
OA/EA (dissolved in pure DMSO) at ~80 % confluency. After 24h total RNA was 
extracted using TRIzol reagent (Invitrogen) following the manufacturer’s instructions. 
The concentration of total RNA was measured using a NanoDrop 1000 
spectrophotometer. Equal amounts (400 ng) of total RNA were used for the cDNA 
synthesis using the miScript Reverse Transcription Kit according to the 
manufacturer's instructions (Qiagen). Real time PCR was performed using 2× 
QuantiTect SYBR Green PCR Master Mix, miScript universal primer, and primers for 
corresponding miRs. We could not assume that OA treatment is neutral towards 
selected small RNAs. For this the levels of miR-7 were normalised to the amount of 
total RNA loaded to each reaction. Alternatively, we performed similar analyses in 
HeLa cells grown in Opti-MEM without serum. Here we used miR-16 as a loading 
control.  
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FIGURE LEGENDS 
FIGURE 1. Oleic Acid and Elaidic Acid remodel the pri-miR-7-1/protein complex 
(a) Molecular structure of OA and EA. (b) Schematic of secondary structure of pri-
miR-7 and CTL of miR-7 (in red) showing the experimentally-derived model for pre-
miR-7-1/HuR/MSI2 complex (Choudhury et al. 2013) (c) Electrophoretic mobility 
shift assay (EMSA) of pre-miR-7-1 in the presence of HeLa cell extracts to 
demonstrate the binding of proteins and to quantitate the effect of increasing 
concentrations of OA and EA treatment on the pre-miR-7-1/protein complex. The 
image is a representative of three independent experiments. Lanes 1 and 6 show 
EMSA with no extract. Lanes 2 and 7 show EMSA with HeLa extract only. Lanes 3, 
4 and 5 represent EMSA with increasing concentration of OA. Lanes 8, 9 and 10 
represent EMSA with increasing concentrations of EA. (d) Densitometry analysis of 
EMSA results to quantitate the effect of OA and EA treatment. Mock represents the 
pre-miR-7-1 incubated with HeLa cell extract only. OA and EA treatment values were 
normalized to values derived from mock treatment. The standard error of the mean (± 
SEM) was calculated using the replicates of three independent experiments. Student’s 
t-test was performed to assess the statistical significance; *P<0.05, **P<0.01. 
 
FIGURE 2. HuR and DHX9 protein are detected in the pre-miR-7/protein complex. 
The figure shows western blot-combined EMSA (WEMSA) of EMSA presented in 
Figure 1 c. (a) HuR and (b) DHX9 were detected using corresponding antibodies. 
Lanes 1 and 6 show WEMSA with no extract. Lanes 2 and 7 show WEMSA with 
HeLa extract only. Lanes 3, 4 and 5 represent WEMSA with increasing concentration 
of OA. Lanes 8, 9 and 10 represent WEMSA with increasing concentrations of EA. 
All WEMSA blots were repeated minimum three times. 
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FIGURE 3. Oleic Acid and Elaidic Acid does not remodel the pre-let-7a-1/protein 
complex. (a) Electrophoretic mobility shift assay (EMSA) of pre-let-7a-1 in the 
presence of HeLa cell extracts and increasing concentrations of OA and EA treatment. 
The image is a representative of three independent experiments. Lanes 1 and 6 show 
EMSA with no extract. Lanes 2 and 7 show EMSA with HeLa extract only. Lanes 3, 
4 and 5 represent EMSA with increasing concentration of OA. Lanes 8, 9 and 10 
represent EMSA with increasing concentrations of EA. (b) Densitometry analysis of 
EMSA results to quantitate the effect of OA and EA treatment. Mock represents the 
pre-let-7a-1 incubated with HeLa cell extract only. OA and EA treatment values were 
normalized to values derived from mock treatment. The standard error of the mean (± 
SEM) was calculated using the replicates of three independent experiments. 
 
FIGURE 4. High concentrations of Oleic Acid and Elaidic Acid affects the pre-miR-
16/protein complex. (a) Electrophoretic mobility shift assay (EMSA) of pre-miR-16 
in the presence of HeLa cell extracts and increasing concentrations of OA and EA 
treatment. The image is a representative of three independent experiments. Lanes 1 
and 6 show EMSA with no extract. Lanes 2 and 7 show EMSA with HeLa extract 
only. Lanes 3, 4 and 5 represent EMSA with increasing concentration of OA. Lanes 8, 
9 and 10 represent EMSA with increasing concentrations of EA. (b) Densitometry 
analysis of EMSA results to quantitate the effect of OA and EA treatment. Mock 
represents the pre-miR-16 incubated with HeLa cell extract only. OA and EA 
treatment values were normalized to values derived from mock treatment. The 
standard error of the mean (± SEM) was calculated using the replicates of three 
independent experiments. Student’s t-test was performed to assess the statistical 
significance; **P<0.01. 
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FIGURE 5. OA and EA inhibit binding of RRM contacting proteins to the miR-7-1 
CTL. The figure shows western blot analysis of miR-7-1 CTL RNA pull-down with 
HeLa cell extract and OA/EA treatment. Selected proteins (MSI2, HuR, hnRNPA1 
and DHX9) were monitored using western blot analysis with corresponding 
antibodies. Lanes 1 and 10 represent the loading control of HeLa cell extract, Lanes 2 
and 11 show beads alone. Lanes 4 and 13, 6 and 15, 8 and 17 show beads incubated 
with 10 μM, 100 μM, 500 μM of OA and EA, respectively. Lanes 3 and 12 represent 
miR-7-1 CTL pull-down. Lanes 5 and 14, 7 and 16, 9 and 18 represent the miR-7-1 
CTL pull-down in HeLa cell extract treated with 10 μM, 100 μM, 500 μM of OA and 
EA, respectively. The experiment has been repeated three times. 
 
FIGURE 6. OA induces pri-miR-7-1 processing in vitro.  In vitro processing of pri-
miR-7-1 (a and b) and pri-miR-16 (c and d) with HeLa extract in the presence of 
different concentrations of OA and EA. The processing of pri-miR-7-1 is increased 
upon (a) OA and (b) EA treatment. Radiolabeled pri-miR-7-1 [~30 × 103 cpm, (counts 
per minute)] transcript was incubated with 50 % w/v total HeLa cell extract and the 
concentration dependent effect of (a) OA and (b) EA treatment was assessed on the 
processing of pri-miR-7-1. The in vitro processing of pri-miR-16 is inhibited upon (c) 
OA and (d) EA treatment. Radiolabeled pri-miR-16 [~30 × 103 cpm, (counts per 
minute)] was incubated with the 50 % w/v total HeLa cell extract and the 
concentration dependent effect of (a) OA and (b) EA treatment was assessed on the 
processing of pri-miR-16. All the products of in vitro transcription were resolved on 8 
% denaturing polyacrylamide gel. Lane 1 in each gel represents the decade marker for 
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RNA size. Lanes 2 and 3 in each gel represent mock treatment and in vitro processing 
reactions, respectively. Lanes 4, 5 and 5 show in vitro processing reaction in 
increasing concentrations of OA and EA as indicated in the figure. These experiments 
were repeated minimum three times. 
 
FIGURE 7. OA induces miR-7 production in HeLa cells. Real time qRT-PCR of 
miR-7 upon treatment of HeLa cells with (a) OA and (b) EA for 24 hrs. Mock 
controls were treated with same volume of pure DMSO as OA/EA treatments. The 
change in levels of miR-7 was calculated relative to the mock treatment. The level 
was normalised to total RNA. Error bars represent the standard error of the mean (± 
SEM) of three independent experimental repeats. Statistical analysis was performed 
by student’s t-test *P < 0.05. (c) Real time qRT-PCR of selected miRs upon OA 
treatment of HeLa cells culture in Opti-MEM without serum. The change in levels of 
miRs was calculated relative to the DMSO treatment. The level was normalised to 
miR-16. Error bars represent the standard error of the mean (± SEM) of three 
independent experimental repeats. Statistical analysis was performed by student’s t-
test *P < 0.05. 
 
